Achilles Therapeutics shares skyrocket 32% after massive cost cuts—Is this the turnaround it needs?
Achilles Therapeutics PLC saw its American Depositary Receipts (ADRs) soar by an impressive 32%, reflecting renewed investor optimism following the company’s recent announcement of stringent cost-cutting measures. This move, which comes at a time of financial strain for many biotech companies, highlights Achilles’ commitment to securing its financial future while advancing its cutting-edge cancer therapies. […]